Literature DB >> 2479185

Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies.

A D Barrett1, A Pryde, A R Medlen, T N Ledger, J E Whitby, C A Gibson, M DeSilva, D J Groves, D J Langley, P D Minor.   

Abstract

Two panels of envelope glycoprotein reactive monoclonal antibodies (mAbs) were prepared against yellow fever (YF) 17D vaccine viruses. Five mAbs were prepared against the World Health Organization 17D-204 avian leukosis virus-free secondary seed virus and eight mAbs against 17DD vaccine manufactured in Brazil. The majority of these mAbs were type-specific and displayed differing reactions in neutralization tests. One, B14, would only neutralize YF vaccine virus grown in invertebrate cells. Others would differentiate 17D-204 and 17DD vaccines, from different manufacturers, in neutralization tests when the viruses were grown in vertebrate cells. The data indicate that heterogeneity exists between the epitopes that elicit neutralizing antibody on YF vaccine from different manufacturers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479185     DOI: 10.1016/0264-410x(89)90196-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.

Authors:  B K Sil; L M Dunster; T N Ledger; M R Wills; P D Minor; A D Barrett
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.

Authors:  Srilatha Edupuganti; Rachel B Eidex; Harry Keyserling; Rama S Akondy; Robert Lanciotti; Walter Orenstein; Carlos del Rio; Yi Pan; Troy Querec; Harvey Lipman; Alan Barrett; Rafi Ahmed; Dirk Teuwen; Martin Cetron; Mark J Mulligan
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

3.  Heterologous Protection against Asian Zika Virus Challenge in Rhesus Macaques.

Authors:  Matthew T Aliota; Dawn M Dudley; Christina M Newman; Emma L Mohr; Dane D Gellerup; Meghan E Breitbach; Connor R Buechler; Mustafa N Rasheed; Mariel S Mohns; Andrea M Weiler; Gabrielle L Barry; Kim L Weisgrau; Josh A Eudailey; Eva G Rakasz; Logan J Vosler; Jennifer Post; Saverio Capuano; Thaddeus G Golos; Sallie R Permar; Jorge E Osorio; Thomas C Friedrich; Shelby L O'Connor; David H O'Connor
Journal:  PLoS Negl Trop Dis       Date:  2016-12-02

Review 4.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

5.  Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism.

Authors:  Emily H Davis; Binbin Wang; Mellodee White; Yan-Jang S Huang; Vanessa V Sarathy; Tian Wang; Nigel Bourne; Stephen Higgs; Alan D T Barrett
Journal:  NPJ Vaccines       Date:  2022-03-23       Impact factor: 9.399

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.